Molecular testing may identify benign disease in some patients with thyroid nodules classified as suspicious for malignancy, helping them avoid unnecessary treatment.
Adherence to the 2015 recommendation from ATA — to use lobectomy rather than complete thyroidectomy for low-risk differentiated thyroid cancer — is increasing.
Malignancy was more common in children with thyroid nodules classified as indeterminate by BSRTC criteria compared with adults.
RET inhibitor LOXO-292 was well tolerated and demonstrated high antitumor activity against RET-altered thyroid cancers.
Childhood radiation-induced thyroid cancer does not affect all-cause mortality compared with healthy individuals.
The addition of selumetinib to radioactive iodine did not improve the complete remission rate among patients with high-risk nonmetastatic differentiated thyroid cancer.
Immune-related gene sets, including those for PD-L1/L2, are upregulated in ATC and PTC, but not in poorly differentiated disease or normal tissue.
Most imaging centers in the United States fail to analyze lateral neck lymph nodes during preoperative ultrasounds in patients with thyroid cancer.
Postoperative radioiodine remnant ablation did not improve long-term outcomes among patients with low-risk papillary thyroid carcinoma.
Outcomes after radioiodine therapy are similar after preparation with either recombinant human thyrotropin or thyroid hormone withdrawal.
Ethanol sensitization before radiofrequency ablation of benign thyroid nodules reduced time, ablation energy, and complications compared with conventional ablation.
High serum soluble PD-L1 levels are associated with shorter disease-free survival among patients with papillary thyroid cancer.
Thyroid-based immune-related adverse events are common among patients treated with PD-L1 inhibitors.
First-Line Pembrolizumab Plus Chemoradiotherapy Found to Be Ineffective in Anaplastic Thyroid CancerOctober 02, 2018
Pembrolizumab plus chemoradiotherapy failed to improve survival and lead to unexpected deaths in a small study of patients with anaplastic thyroid cancer.
The TRK inhibitor larotrectinib was effective and well tolerated among patients with relapsed/refractory advanced TRK-fusion thyroid cancer.
Tumor suppressor and driver genes are frequently mutated in Korean patients with anaplastic thyroid cancer.
Postoperative Radioactive Iodine Ablation Effective in Reducing Disease Recurrence in Low-Risk Thyroid CancerJune 20, 2018
For patients with low-risk thyroid cancer, ablation when indicated could be achieved with 1.1 GBq radioactive iodine after recombinant human thyroid-stimulating hormone (rhTSH) injections, as this combination reduces whole body irradiation and maintains quality of life.
Thymic carcinomas typically express high levels of PD-L1, leading researchers to predict a positive response to pembrolizumab.
The risk of AML decreased after 2 years, returning to baseline within 6 years of WDTC diagnosis, but the risk of CML remained elevated for up to 10 years.
Researchers enrolled 116 patients who were diagnosed with or were suspected of having thyroid cancer. The authors measured the growths' change in diameter to determine a growth pattern.
Patients with ATC have a very poor prognosis and are left with few systemic therapy options.
Significant clinical benefit was found in some patients treated with cabozantinib in the salvage setting.
The USPSTF stated that there was inadequate direct evidence for the benefits of screening.
Researchers are studying regorafenib, a multi kinase inhibitor, as treatment for metastatic medullary thyroid cancer.
Thyroid cancer survivors diagnosed prior to age 40 have an increased risk of developing diseases associated with aging.
Patients with unresected anaplastic thyroid carcinoma who receive greater than 60 Gy of radiation appear to have a longer median overall survival.
Crohn Disease (CD) may increase one's risk of thyroid cancer, according to an article published in Inflammatory Bowel Diseases.
The USPSTF recommends against population-wide screening for asymptomatic thyroid cancer.
For papillary thyroid cancer (PTC), patient age is associated with death in a linear fashion, with no apparent age cut point demarcating survival difference.
Embracing all the myriad variations of the human genome should, in theory, lead to rewards that all can share.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified
- Gly101Val Mutation Directly Causes Resistance to Venetoclax
- Can Treatments for Childhood ALL Alter the Gut Microbiome?